Browse the evidence

Gene-by-environment interactions are the primary drivers of body weight regulation, and neither the set point nor settling point models fully explain obesity without considering these interactions.

Your weight is determined by how your specific genetics respond to your specific environment. You cannot change your genes, but you can change your environment. Effective weight management requires recognizing that what works for one person (genotype) in one environment may not work for another, and interventions must be tailored to this interaction.

Chronic metabolic stress from aging and high-fat feeding causes systemic carnitine insufficiency, characterized by reduced skeletal muscle free carnitine levels and compromised mitochondrial fuel switching.

Aging and chronic overeating can deplete your body's natural carnitine stores, particularly in muscle. This depletion impairs your mitochondria's ability to switch between burning fat and sugar efficiently, contributing to insulin resistance.

Activation of pro-opiomelanocortin (POMC) neurons in the arcuate nucleus suppresses food intake and increases energy expenditure via the central melanocortin pathway.

Your body uses specific brain neurons (POMC) to tell you when to stop eating and burn energy. These neurons respond to hormones like leptin. Understanding this biology helps explain why dieting is hard—it's not just willpower, it's a biological circuit.

Activation of neuropeptide Y/agouti-related peptide (NPY/AgRP) neurons increases food intake primarily by releasing GABA to inhibit anorexigenic centers.

Your brain has 'hunger neurons' (NPY/AgRP) that actively suppress 'fullness' signals by releasing GABA. This biological drive is a primary regulator of food intake.

Genetic variants that increase body fat percentage (BF%) have distinct, locus-specific effects on cardiometabolic disease risk, meaning that increased adiposity does not uniformly increase disease risk and can sometimes be protective depending on the genetic mechanism.

Your body fat percentage alone is not a perfect predictor of your metabolic health. Your genetics influence how that fat affects your risk for diabetes and heart disease. Some genetic profiles that lead to higher body fat may actually be protective against certain metabolic issues, while others may increase risk. Focus on overall metabolic markers (like blood pressure, lipids, and blood sugar) rather than just body fat percentage to assess health.

Macrophage accumulation and polarization towards a proinflammatory (M1-like) state in adipose tissue is the dominant mechanism driving insulin resistance in obesity.

Your fat cells aren't just storage; they recruit immune cells called macrophages when overfilled. These macrophages release inflammatory signals that block insulin. Reducing this inflammation, potentially through weight loss or anti-inflammatory strategies, is crucial for fixing insulin resistance.

Higher cumulative energy intake (caloric dose) during the first week of ICU stay is inversely associated with recovery speed; the lowest caloric doses are associated with the fastest recovery.

When managing nutrition in the first week of critical illness, aiming for high caloric targets is counterproductive. Data shows a linear relationship where higher calorie intake leads to slower recovery. Clinicians should prioritize tolerating lower caloric intakes (hypocaloric feeding) rather than aggressively pushing calories, as this is associated with faster ICU discharge.

Increased adiposity (BMI) within the normal to overweight range (non-obese) causally alters the systemic metabolite profile, adversely affecting cardiometabolic risk markers including lipoprotein subclasses, amino acids, and inflammatory markers.

If you are in your 20s or 30s and your BMI is in the overweight range (even if not obese), your body's metabolic chemistry is likely already shifting in ways that increase long-term health risks. This isn't just about weight; it's about how your body processes fats and sugars. Maintaining a healthy weight now can prevent these metabolic shifts from becoming entrenched.

Overall US adult obesity prevalence increased significantly from 2011 to 2018, with non-Hispanic Black individuals showing the highest prevalence but leveling off trends.

Overall obesity rates in the US are rising. To maintain health, focus on sustainable lifestyle changes such as balanced nutrition and regular physical activity, regardless of broader demographic trends.

Sarcopenia is defined by a combination of muscle weakness, low muscle mass, and impaired physical performance (e.g., slow walking speed), with prevalence ranging from 4% to 27% in older populations.

Sarcopenia isn't just 'getting old'; it's a specific condition defined by weakness, low muscle mass, and slow walking. Screening for these metrics can help identify at-risk individuals for early intervention.

Dietary intake measurements provide only a guide to, and not a direct measure of, the amounts of energy and nutrients available for metabolism.

Understand that dietary tracking is an estimate, not a precise measurement of what your body uses. Use it to identify trends and patterns rather than obsessing over the exact calorie or nutrient count, as food intake does not equal metabolic availability.

Natural experiments with weaker study designs (cross-sectional, case-only) are more likely to report positive associations with interventions than those with strong designs (longitudinal with comparison groups).

Be skeptical of positive findings from single-site, cross-sectional studies of policy changes. Prioritize longitudinal studies with comparison groups for evidence-based decision making.

Reducing dietary saturated fatty acid intake leads to a stepwise increase in plasma Lipoprotein(a) [Lp(a)] concentrations.

Be aware that significantly lowering saturated fat can raise Lipoprotein(a), a specific cardiovascular risk factor. If you have high Lp(a), discuss this trade-off with your doctor when making dietary changes.

High-protein diets are not recommended by the AHA because they restrict healthful foods, leading to nutrient deficiencies and potential long-term health risks.

Do not follow a high-protein diet that eliminates major food groups like fruits, vegetables, and grains. These foods provide essential nutrients and fiber. A balanced diet that creates a caloric deficit is safer and more sustainable.

Leptin acts as an anorexigenic signal by binding to LEPRb in the hypothalamus, activating the JAK2/STAT3 and PI3K pathways to stimulate POMC and inhibit AgRP neurons, thereby reducing food intake and increasing energy expenditure.

Your body produces leptin to tell your brain you are full. In obesity, this signal often gets ignored (leptin resistance). You cannot simply 'take' leptin to fix this. Focus on strategies that may improve insulin sensitivity and reduce inflammation, which are linked to leptin signaling, rather than seeking leptin-based supplements which are ineffective for most.

Ghrelin acts as an orexigenic signal by binding to GHSR on AgRP neurons in the arcuate nucleus, stimulating NPY and AGRP expression and increasing food intake and adiposity.

Ghrelin is your body's 'hunger hormone,' released by the stomach when empty. It signals the brain to eat. In obesity, ghrelin levels are often lower than expected, yet hunger persists, suggesting complex brain resistance. Understanding that hunger is a normal signal helps distinguish between physical need and emotional eating.

GLP1, secreted from intestinal L-cells after meals, acts as an anorexigenic signal by activating GLP1 receptors in the hypothalamus and brainstem, inhibiting food intake via vagal afferents and central circuits.

GLP-1 is a hormone your gut releases after eating to help you feel full. Modern medications mimic this hormone to enhance its effect, leading to reduced appetite and weight loss. This works by acting on both the gut nerves and the brain.

During caloric overfeeding, dietary protein intake (5-25% of energy) does not significantly affect the amount of body fat gained; fat gain is determined by caloric surplus alone.

If you are eating in a caloric surplus, your body will store the excess energy as fat regardless of how much protein you eat. High protein diets do not prevent fat gain during overfeeding; they only change how much of the total weight gain is fat versus muscle and how much energy is burned.

Central administration of Neuropeptide Y (NPY) acts as a potent orexigenic signal that stimulates food intake, specifically increasing carbohydrate preference, reducing the latency to eat, and delaying satiety to augment meal size.

Neuropeptide Y (NPY) is a brain chemical that strongly drives hunger, specifically for carbohydrates. It works by making you start eating sooner, motivating you to work harder for food, and making you feel full later than usual, leading to larger meals. This is a central brain mechanism, not triggered by eating NPY from food.

Fasting and energy restriction upregulate the NPY system (increasing mRNA and peptide content in the arcuate nucleus), while refeeding and high-fat/high-energy diets tend to downregulate or decrease NPY expression as a counter-regulatory mechanism.

Your brain's hunger signal (NPY) increases when you fast or restrict calories to drive you to eat. However, chronic overconsumption of high-fat or high-energy foods may actually suppress this specific signal over time as a counter-regulatory response.

Defective lipid storage capacity in white adipose tissue, often due to impaired expansion or PLIN dysfunction, leads to ectopic fat deposition in non-adipose tissues, causing insulin resistance and type 2 diabetes.

Your body relies on fat cells (adipose tissue) to safely store excess energy. If these cells cannot expand or function properly (due to genetics or chronic overloading), fat spills over into organs like the liver and muscles. This 'spillover' causes insulin resistance and type 2 diabetes. Therefore, maintaining healthy fat cell function is as important as reducing total fat mass.

AgRP neurons promote feeding and inhibit energy expenditure by antagonizing MC4R, and their activity is increased during fasting/starvation.

During fasting, your body activates AgRP neurons to drive hunger and conserve energy. This is a normal survival mechanism. Understanding this helps explain why hunger increases when you restrict calories.

Rosiglitazone, a thiazolidinedione that increases insulin sensitivity by activating PPAR-gamma, delays monotherapy failure and preserves beta-cell function more effectively than metformin or glyburide in patients with recently diagnosed type 2 diabetes.

For newly diagnosed type 2 diabetics, rosiglitazone (8mg/day) may offer better long-term preservation of the pancreas's ability to produce insulin compared to metformin or glyburide, potentially delaying the need for additional medications. This benefit comes with the trade-off of potential side effects like weight gain or fluid retention, which should be monitored.

Continuous Positive Airway Pressure (CPAP) therapy for Obstructive Sleep Apnoea (OSA) results in a statistically significant, albeit small, increase in body weight and Body Mass Index (BMI) compared to control conditions.

If you start CPAP for sleep apnea, expect a small amount of weight gain (average ~0.4 kg in the studies, but variable). This is likely because your body is no longer burning extra energy fighting breathing interruptions and your sleep hormones (growth hormone/cortisol) are normalizing. To counter this, proactively combine CPAP with standard weight management strategies like diet and exercise, rather than stopping CPAP.